GLP-1 Use Among Young Children With Obesity in US Remains Rare but Is Rising Rapidly

Data ReadoutSaxendaWegovyZepboundPositive

AI Analysis

Summary

GLP-1 weight loss drugs (Saxenda, Wegovy, Zepbound) are being prescribed to US children under age 12 with obesity at a rate 310 times higher in June 2026 compared to 2019, though absolute numbers remain low.

Outcome Details

GLP-1 prescriptions for US children under age 12 increased 310 times from 2019 to June 2026

Importance:3/10

Sentiment:

0.30

GLP-1pediatric obesityweight loss drugsprescribing trendsmarket adoption

Related Companies

$NVO $LLY

Read the original article

Published by PR Newswire Clinical Trials on September 4, 2026 10:12 AM

Read Original